Wang G, Liu P, Xie H, Niu C, Lyu J, An Y
J Inflamm Res. 2024; 17:7627-7637.
PMID: 39479263
PMC: 11521778.
DOI: 10.2147/JIR.S478520.
Mia M, Howlader M, Akter F, Hossain M
Clin Pathol. 2024; 17:2632010X241263054.
PMID: 39070952
PMC: 11282570.
DOI: 10.1177/2632010X241263054.
Erickson M, Boone T, Nadworny P
Viruses. 2024; 16(6).
PMID: 38932251
PMC: 11209601.
DOI: 10.3390/v16060959.
Meng Q, Tai W, Tian M, Zhuang X, Pan Y, Lai J
Sci Adv. 2023; 9(24):eadg3277.
PMID: 37315135
PMC: 10266725.
DOI: 10.1126/sciadv.adg3277.
Li G, Hilgenfeld R, Whitley R, De Clercq E
Nat Rev Drug Discov. 2023; 22(6):449-475.
PMID: 37076602
PMC: 10113999.
DOI: 10.1038/s41573-023-00672-y.
Synthesis of Microwave Functionalized, Nanostructured Polylactic Co-Glycolic Acid (PLGA) for Incorporation into Hydrophobic Dexamethasone to Enhance Dissolution.
Islam M, Mitra S
Nanomaterials (Basel). 2023; 13(5).
PMID: 36903820
PMC: 10005067.
DOI: 10.3390/nano13050943.
Artificial intelligence assessment of the potential of tocilizumab along with corticosteroids therapy for the management of COVID-19 evoked acute respiratory distress syndrome.
Segu-Verges C, Artigas L, Coma M, Peck R
PLoS One. 2023; 18(2):e0280677.
PMID: 36791125
PMC: 9931125.
DOI: 10.1371/journal.pone.0280677.
Prolonged COVID-19 in a Multiple Sclerosis Patient Treated With Rituximab.
Kintrilis N, Gkinos C, Galinos I
Cureus. 2023; 14(12):e32523.
PMID: 36654638
PMC: 9840416.
DOI: 10.7759/cureus.32523.
A hyperinflammation clinical risk tool, HI5-NEWS2, stratifies hospitalised COVID-19 patients to associate risk of death and effect of early dexamethasone in an observational cohort.
Ardern-Jones M, Phan H, Borca F, Stammers M, Batchelor J, Reading I
PLoS One. 2023; 18(1):e0280079.
PMID: 36649371
PMC: 9844906.
DOI: 10.1371/journal.pone.0280079.
Integrative Investigation Reveals the Host-Virus Interactions in Repurposed Drugs Against SARS-CoV-2.
Yu W, Bai Y, Raha A, Su Z, Geng F
Front Bioinform. 2022; 1:763540.
PMID: 36303774
PMC: 9580895.
DOI: 10.3389/fbinf.2021.763540.
Evolution of Care and Outcomes Across Surges in Hospitalized Patients with Coronavirus Disease 2019.
OHayer P, Vasbinder A, Anderson E, Catalan T, Bitterman B, Khaleel I
Am J Med. 2022; 136(1):63-71.e1.
PMID: 36150511
PMC: 9489963.
DOI: 10.1016/j.amjmed.2022.08.035.
Is hemolysis a novel therapeutic target in COVID-19?.
Ousaka D, Nishibori M
Front Immunol. 2022; 13:956671.
PMID: 36059481
PMC: 9438449.
DOI: 10.3389/fimmu.2022.956671.
COVID-19 immunopathology: From acute diseases to chronic sequelae.
Arish M, Qian W, Narasimhan H, Sun J
J Med Virol. 2022; 95(1):e28122.
PMID: 36056655
PMC: 9537925.
DOI: 10.1002/jmv.28122.
Medicinal nicotine in COVID-19 acute respiratory distress syndrome, the new corticosteroid.
Ahmad F
World J Crit Care Med. 2022; 11(4):228-235.
PMID: 36051943
PMC: 9305679.
DOI: 10.5492/wjccm.v11.i4.228.
Metabolomics Markers of COVID-19 Are Dependent on Collection Wave.
Lewis H, Liu Y, Frampas C, Longman K, Spick M, Stewart A
Metabolites. 2022; 12(8).
PMID: 36005585
PMC: 9415837.
DOI: 10.3390/metabo12080713.
Glucocorticoid therapy in respiratory illness: bench to bedside.
Amratia D, Viola H, Ioachimescu O
J Investig Med. 2022; 70(8):1662-1680.
PMID: 35764344
PMC: 9726965.
DOI: 10.1136/jim-2021-002161.
Adverse Audio-Vestibular Effects of Drugs and Vaccines Used in the Treatment and Prevention of COVID-19: A Review.
Skarzynska M, Matusiak M, Skarzynski P
Audiol Res. 2022; 12(3):224-248.
PMID: 35645195
PMC: 9149960.
DOI: 10.3390/audiolres12030025.
Advances in Pathogenesis, Progression, Potential Targets and Targeted Therapeutic Strategies in SARS-CoV-2-Induced COVID-19.
Zhou H, Ni W, Huang W, Wang Z, Cai M, Sun Y
Front Immunol. 2022; 13:834942.
PMID: 35450063
PMC: 9016159.
DOI: 10.3389/fimmu.2022.834942.
Stem Cell-based therapies for COVID-19-related acute respiratory distress syndrome.
Ngai H, Kim D, Hammad M, Gutova M, Aboody K, Cox C
J Cell Mol Med. 2022; 26(9):2483-2504.
PMID: 35426198
PMC: 9077311.
DOI: 10.1111/jcmm.17265.
Treatment of severe COVID-19 patients with either low- or high-volume of convalescent plasma standard of care: A multicenter Bayesian randomized open-label clinical trial (COOP-COVID-19-MCTI).
Song A, Rocha V, Mendrone-Junior A, Calado R, De Santis G, Benites B
Lancet Reg Health Am. 2022; 10:100216.
PMID: 35308034
PMC: 8923059.
DOI: 10.1016/j.lana.2022.100216.